Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Faithful modeling of terminal CD8+T cell dysfunction and epigenetic stabilization in vitro
Amir Yousif, … , Eugene M. Oltz, Hazem E. Ghoneim
Amir Yousif, … , Eugene M. Oltz, Hazem E. Ghoneim
Published October 8, 2025
Citation Information: JCI Insight. 2025;10(19):e191220. https://doi.org/10.1172/jci.insight.191220.
View: Text | PDF
Research Article Immunology Oncology

Faithful modeling of terminal CD8+T cell dysfunction and epigenetic stabilization in vitro

  • Text
  • PDF
Abstract

Epigenetic scarring of terminally dysfunctional (TDysf) CD8+ T cells hinders long-term protection and response to immune checkpoint blockade during chronic infections and cancer. We developed a faithful in vitro model for CD8+ T cell terminal dysfunction as a platform to advance T cell immunotherapy. Using TCR-transgenic CD8+ T cells, we found that 1-week peptide stimulation, mimicking conditions in previous models, failed to induce a stable exhaustion program. In contrast, prolonged stimulation for 2–3 weeks induced T cell dysfunction but triggered activation-induced cell death, precluding long-term investigation of exhaustion programs. To better mimic in vivo exhaustion, we provided post-effector, chronic TGF-β1 signals, enabling survival of chronically stimulated CD8+ T cells for over 3 weeks. These conditions induced a state of terminal dysfunction, marked by a stable loss of effector, cytotoxicity, and memory programs, along with mitochondrial stress and impaired protein translation. Importantly, transcriptomic and epigenetic analyses verified the development of terminal exhaustion-specific signatures in TDysf cells. Adoptive transfer of TDysf cells revealed their inability to recall effector functions or proliferate after acute lymphocytic choriomeningitis virus rechallenge. This tractable model system enables investigation of molecular pathways driving T cell terminal dysfunction and discovery of therapeutic targets for cancer or chronic infections.

Authors

Amir Yousif, Abbey A. Saadey, Ava Lowin, Asmaa M. Yousif, Ankita Saini, Madeline R. Allison, Kelley Ptak, Eugene M. Oltz, Hazem E. Ghoneim

×

Figure 7

Dysfunction of in vitro–generated TDysf cells is irreversible during in vivo rechallenge.

Options: View larger image (or click on image) Download as PowerPoint
Dysfunction of in vitro–generated TDysf cells is irreversible during in ...
(A) Schematic for adoptive transfer of “Acute-7d” (blue) or “TDysf” (red) P14 cells into congenically distinct C57BL/6 mice on day 19, followed by acute LCMV infection and analysis on day 6–7 postinfection. (B) Total P14 cell numbers from spleens, livers, and lungs. Panels C–G and I–N are for spleens. (C) Bar graph showing expression level (gMFI) of Ly108 or (D) % Ifnγ+ P14 cells after ex vivo GP33 peptide rechallenge. (E) Representative FACS plots showing Ifnγ and Perforin expression and summary bar graph showing % Ifnγ+Perforin+ P14 cells. (F) Bar graph showing expression level (gMFI) of Gzmb or (G) TOX. (H) Schematic for adoptive transfer of “Rested Acute-7d” (dark blue) or “Rested TDysf” (dark red) P14 cells on day 26 into congenically distinct C57BL/6 mice, followed by acute LCMV infection and analysis on day 6–7 postinfection. (I) Bar graph showing total number of P14 cells isolated from spleens or (J) expression level (gMFI) of Ly108. (K) Representative FACS plots showing Ifnγ and Tnf or CD107a expression and summary bar graph showing % of Ifnγ+Tnf+ or Ifnγ+CD107a+ P14 cells. (L) Representative FACS plots showing PD-1 and Tim3 expression and (M) summary bar graph showing % of PD-1+Tim3+ P14 cells. (N) Bar graph showing the expression level (gMFI) of Gzmb. For all FACS plots (E, K, and L), Acute-7d plots are representative of 1 recipient mouse, while the TDysf plots show data combined from all TDysf recipient mice. For B, data were pooled from 2 independent experiments with n = 3–5 biological replicates per group for each experiment. For all other panels, n = 4–6 biological replicates from 2 to 3 independent experiments. Adjusted P value *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Comparisons were determined by Mann-Whitney U test (unpaired, 2-sided). Error bars indicate mean ± SEM.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts